Sign In
Buy GPCR
$48.04
-1.43 (-2.89%)
At Close: Jul 31, 2026
SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
11:20am, Friday, 17'th Apr 2026
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%. Although increasingl
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
04:05pm, Tuesday, 14'th Apr 2026
SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me
Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat
04:14pm, Wednesday, 08'th Apr 2026
Structure Therapeutics (GPCR) is initiated with a BUY rating and $110 price target, reflecting a 101% upside from current levels. Aleniglipron, GPCR's oral GLP-1 agonist, demonstrated 16.3% placebo-ad
Capricorn Fund Managers Ltd Invests $17.57 Million in Structure Therapeutics Inc. Sponsored ADR $GPCR
04:43am, Monday, 06'th Apr 2026
Capricorn Fund Managers Ltd bought a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR) during the fourth quarter, according to the company in its most recent disclosure w
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages
04:08am, Saturday, 04'th Apr 2026
Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eighteen research firms that are currently cove
What's Going On With Structure Therapeutics Stock On Wednesday?
02:07pm, Wednesday, 01'st Apr 2026
• What's the outlook for GCPR shares?
These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
07:35am, Wednesday, 01'st Apr 2026
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech lands
Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster
08:15am, Friday, 27'th Mar 2026
Structure Therapeutics reported Phase 2 data for Aleniglipron, showing 16% weight loss at 44 weeks with strong tolerability and no safety signals. Aleniglipron's best-in-class oral efficacy, low disco
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
11:56am, Monday, 23'rd Mar 2026
Novo Nordisk faces slowing growth and rising competition, while Structure Therapeutics shows strong obesity study results, highlighting a clash of stability vs. upside.
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
04:06pm, Sunday, 22'nd Mar 2026
B Group acquired 90,000 shares of Structure Therapeutics in the fourth quarter. The quarter-end position value increased by $6.26 million due to the new holding.
Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target
07:45am, Tuesday, 17'th Mar 2026
Structure Therapeutics (GPCR) reported highly positive Phase 2 ACCESS II data for aleniglipron, achieving ~16% placebo-adjusted weight loss with strong statistical significance and no plateau. Alenigl
Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript
Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate?
10:46am, Monday, 16'th Mar 2026
Structure Therapeutics said its GLP-1 pill helped patients lose more than 16% of their body weight in a midstage trial, outperforming results reported for competing obesity drugs.
Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16%
09:27am, Monday, 16'th Mar 2026
The stock's rise comes as the company reported significant weight loss results from its investigational oral drug, aleniglipron, which is designed for treating obesity, while broader markets experienc
